Introduction
============

Nonalcoholic fatty liver disease (NAFLD) is a manifestation of the metabolic syndrome and is associated with very common conditions such as obesity, type 2 diabetes, hypertension, dyslipidemia, and atherosclerosis [@bib1]. NAFLD includes the mere accumulation of lipid within hepatocytes (hepatic steatosis, HS), or the inflammation of the liver (nonalcoholic steatohepatitis, NASH), liver fibrosis, or cirrhosis [@bib2]. The evolution of HS to NASH occurs through the development of insulin resistance, by accumulation of fat in visceral tissue, and increased oxidative stress, with the consequent development of hepatitis [@bib3]. High leptin and low adiponectin levels have also been associated with this evolution [@bib4]. The consequences of NAFLD on mortality are an issue of debate [@bib5], as this can be influenced by variable definitions and associated conditions. Cardiovascular mortality is increased in NASH cirrhosis compared with other types of cirrhosis, and the incidence of associated hepatocellular carcinoma is higher than 10% in 5 years [@bib6]. It is therefore important to define the causes of NAFLD.

Adult-onset GH deficiency (AOGHD) constitutes a specific model of metabolic syndrome [@bib7], with visceral obesity, insulin resistance, accelerated atherosclerosis, and increased cardiovascular mortality [@bib9]. AOGHD has been associated with NAFLD [@bib10]. Some of the effects of GH are mediated by circulating IGF1, which is mostly of liver origin. IGF1 circulates bound to six IGF1-binding proteins, mainly IGFBP3. Low serum levels of GH or IGF1 and IGF1/IGFBP3 ratio (reflecting low IGF1 bioavailability) have been hypothesized to contribute to NAFLD in AOGHD [@bib13]. However, congenital (vs acquired) isolated GH deficiency (IGHD) may have different consequences in terms of NAFLD.

In Itabaianinha County, in the Brazil Northeast, we have identified a large cohort of patients (more than 100 over seven generations) with congenital IGHD due to a homozygous mutation (c.57+1G→A) in the GHRH receptor gene (*GHRHR*) [@bib15]. These subjects have very low circulating serum IGF1 levels and could therefore be predisposed to developing NAFLD [@bib16]. Despite abdominal obesity and unfavorable cardiovascular risk profile (high total and LDL-C and high C-reactive protein) [@bib17], they have increased insulin sensitivity [@bib19], high adiponectin and normal leptin serum levels [@bib20], no evidence of premature atherosclerosis [@bib21], and normal longevity [@bib22]. As NAFLD is related to insulin resistance, we hypothesized that, despite low IGF1, NAFLD would be absent or mild in this model. The aim of this work was to assess the liver status of these subjects.

Subjects and methods
====================

Subjects
--------

This was a cross-sectional study conducted in Itabaianinha County in the Northeastern Brazilian state of Sergipe. We recruited volunteers (aged 20--59 years) through advertisement placed in the local Dwarfs Association building, and through communication with subjects. Inclusion criteria for IGHD were short stature and genotype-proven homozygosity for the c.57+1G→A *GHRHR* mutation, whereas COs were normal-statured individuals proven to be homozygous for the WT *GHRHR* allele. For both groups, exclusion criteria were a history of current or past excessive alcohol intake (defined by an average daily consumption of more than 20 g of alcohol), % fat mass below 20% and above 50%, diabetes mellitus, use of glucocorticoids, GH, and thyroid hormones, positive hepatitis B and C serology, and inherited, autoimmune, cholestatic, or drug-induced liver disease. Individuals had been previously matched for age, sex, and percentage of fat mass (assessed by DXA) [@bib23]. From the 53 IGHD adult living individuals identified previously [@bib22], two declined, 16 were excluded by age criterion, nine by GH treatment, one for alcoholism, one because of portal hypertensions due to *Schistosoma mansoni*, and two because of fat mass lower than 20%. Therefore, 22 IGHD and 25 CO volunteers were enrolled.

The Federal University of Sergipe Institutional Review Board approved these studies, and all subjects gave written informed consent.

Study protocol
--------------

### Anthropometric measurement

The subjects\' height and weight were measured using a wall-mounted stadiometer (Digital Wall Mounted Stadiometer, Model HM210D, Charder Medical Weighing and Measuring Products, Taichung City Taiwan, R.O.C) and scale (Charder MS2510 Platform Scale). Waist circumference was measured at half the distance between the last rib and the superior margin of iliac crest, and hip circumference was measured at the level of femoral trochanters. Height, weight, and BMI were converted to SDSs using the website <http://www.phsim.man.ac.uk/SDSCalculator/SDSCalculator.aspx>.

### Sonography

Sonographic measurements were all performed by a single radiologist (T O F), using Medison Sono Ace 8000SE (Samsung, Seoul, South Korea), with a 3.5 MHz convex-array probe. The probe was touched as adjusted in such a way that the liquid contents of the gall bladder and the blood in the inferior vena cava were nonechogenic. Gain curve was adjusted to the neutral position. The patient was placed supine and the probe was placed on the right hypochondrium in the longitudinal, transverse, and oblique planes. To diagnose HS, we used a hyperechogenic pattern (HP) coded as follows: 0, absent; 1, mild (hepatic parenchyma with a subtle increase in echogenicity and sound beam attenuation and a subtle decrease in the visualization of the diaphragm and intrahepatic vascularization); 2, moderate (hepatic parenchyma with a moderate increase in echogenicity and sound beam attenuation and a moderate decrease in the visualization of the diaphragm and intrahepatic vascularization); and 3, severe (hepatic parenchyma with a increase in echogenicity and sound beam attenuation, with a marked or complete loss of the visualization of the diaphragm and of the intrahepatic vascularization) [@bib24]. The sonographer was blinded to the laboratory data, but it was impossible to blind him to the IGHD phenotype, due to the severe height reduction. One subject in each group did not undergo ultrasound imaging.

### Laboratory analyses

Fasting blood samples were collected between 0700 and 0900 h. Alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamyl transpeptidase (GGT), total cholesterol and fractions, triglycerides, fibrinogen, prothrombin time (PT), international normalized ratio (INR), prothrombin activity (PA), and activated partial thromboplastin time (APTT) were determined by standard laboratory techniques. AST and ALT were divided by the respective upper limit (AST/upper limit and ALT/upper limit respectively). Anti-HBC IgM, HbsAg, and anti-HCV were measured by electrochemiluminescence, ELECSYS 2010 (Roche Diagnostics). IGF1 was measured by a solid-phase, enzyme-labeled chemiluminescent immunometric assay IMMULITE 2000 (Siemens Healthcare Diagnostics Products Ltd, Malvern, PA, USA), with a sensitivity of 25 ng/ml. Intra- and interassay variabilities were 3.1 and 6.1% respectively. All the tests were carried out in the Laboratory of University Hospital of the Federal University of Sergipe, in Aracaju, capital of Sergipe state.

Statistical analysis
--------------------

Data are expressed as mean±[s.d]{.smallcaps}. Continuous variables were compared by the independent-samples *t-*test and categorical and not normal variables (triglycerides) by the Mann--Whitney *U* test. Percentages were compared by Fisher\'s exact test. The SPSS/PC 15.0 software (SPSS, Inc.) was used. *P* values \<0.05 were considered significant.

Results
=======

Demographic and anthropometric data are given in [Table 1](#tbl1){ref-type="table"}. IGHD and COs were of similar age and sex and have a similar BMI. As expected, IGHD subjects had lower height and weight, but had a higher waist/hip ratio than COs. Laboratory and sonography data are given in [Table 2](#tbl2){ref-type="table"}. IGF1 levels were extremely low in IGHD individuals, and 16 out of 22 IGHD individuals had values below the limit of sensitivity of 25 ng/ml. These values were assumed to be 25 for the purpose of the statistical analyses. IGHD subjects had higher total and LDL-C, lower PT, and similar HDL-C, triglycerides, γ-GT, APTT, and fibrinogen values compared with COs.

Average ALT values were similar in the two groups, while AST was higher in IGHD subjects. However, more IGHD subjects (7/22) than COs (3/23) had an ALT/upper limit of normal ratio above one (*P*=0.044): four IGHD subjects (1.04, 1.13, 1.29, and 1.87) and three COs (1.20, 1.33, and 1.42) less than twice, and three IGHD subjects more than twice (2.09, 2.20, and 2.67). Four IGHD subjects (1.00, 1.13, 1.82, and 1.85) and one CO individual (1.31) had an AST/upper limit ratio above one. No individual in either group had an AST/upper limit ratio higher than two. While the average HP score was higher in IGHD subjects than COs (*P*=0.041), severe NAFLD was not observed in any IGHD (or CO) individual. It has been observed that 61% of IGHD subjects (13/21) had HS (ten mild and three moderate), while only 29% of COs (7/24) had HS (five mild and two moderate) (*P*\<0.032).

Discussion
==========

NAFLD is a very important public health care problem, linked to several common conditions such as visceral obesity, diabetes, atherosclerosis, and increased cardiovascular mortality. NAFLD can evolve to NASH, liver fibrosis, and cirrhosis and, eventually, to liver failure, becoming an important cause of liver transplantation [@bib4].

Our data show that NAFLD is more frequent (although sonographic and biochemically mild) in individuals with severe congenital IGHD than in indigenous controls, matched by fat mass % and BMI, but with higher WHR. Such increase in WHR is due to a specific increase in visceral adiposity [@bib23].

HS, together with insulin resistance, is correlated with downregulation of the GH signaling. The epidermal growth factor receptor (EGFR) signaling system is a key player in all stages of the liver response to injury, from early inflammation and hepatocellular proliferation to fibrogenesis and neoplastic transformation [@bib24]. The EGFR receptor heterodimerizes with the IGF1 receptor, playing major roles in liver responses to injury [@bib24]. The GH/EGFR pathway downregulation is probably the mechanism responsible for liver regeneration deficiency associated with HS, which can be partially rescued in *ob*/*ob* mice by GH administration [@bib25]. Although GH treatment has a positive regenerative effect on the liver after hepatic resection [@bib25], its efficacy in reducing NAFLD in hypopituitarism is controversial, with positive [@bib26] and negative [@bib28] reports. Furthermore, IGF1 treatment does not improve NAFLD in individuals with Laron dwarfism, a known model of GH resistance [@bib29].

Hypopituitarism (often with GHD) has been associated with NAFLD [@bib30], but it is not clear whether NAFLD is a consequence of GHD (and IGF1 deficiency), or whether they are both unrelated consequences of hypopituitarism. It has been shown, using liver biopsy and the hyaluronic acid as a fibrosis marker, that GH may be involved in the mechanism of triglyceride secretion from hepatocytes. Therefore, low levels of IGF1 and low IGF1/IGFBP3 ratio (reflecting low IGF1 bioavailability) may be associated with the accumulation of lipids and advanced fibrosis in NAFLD [@bib14]. We have previously shown that IGHD individuals from the Itabaianinha cohort have very low serum GH and IGF1 levels, but have a high total IGF1+IGF2/IGFBP3 molar ratio (due to a compensatory increase in IGF2/IGFBP3 molar ratio) [@bib16]. We therefore hypothesize that this high IGF1+IGF2/IGFBP3 molar ratio, resulting in high total (IGF1+IGF2) bioavailability, could slow down the evolution form HS to fibrosis or cirrhosis.

As a whole, IGHD subjects have higher serum AST, and the number of individuals with ALT above the normal values was higher in IGHD than COs. The lower PT may indicate higher synthesis of prothrombin by the liver, without obvious clinical relevance. Therefore, we conclude that, while IGHD subjects have more NAFLD than controls, there is no evolution to severe stages of NAFLD. Although we did not perform liver biopsies, the gold standard method to diagnose NAFLD, a comprehensive biochemical and clotting liver evaluation, supports our conclusion of a mild NAFLD pattern in these IGHD subjects. The HS frequency of our IGHD subjects (61%) was similar to that reported (55%, 6/11) in adult patients with Laron dwarfism (GH resistance). The severity of HS was also similar (mild in 48% of our IGHD and in 45% of Laron dwarfs). Interestingly, because the presence of NAFLD was found not to correlate with age, sex, degree of obesity, blood lipids, HOMA-IR, and therapy by statins or IGF1, the data were reported by Prof. Laron to be 'not fitting with present theories of the development of fatty liver [@bib29]'. Our data agree with their conclusion on the difficulty in differentiating between the influences of longstanding GH/IGF1 deficiency and other factors on the development of NAFLD.

Among patients with hypothalamic and pituitary dysfunction, NAFLD was diagnosed with a median of 3 years after the diagnosis of pituitary dysfunction, with a high prevalence of cirrhosis and liver-related death [@bib4]. Given the relatively young age of the subjects studied in this work, one possibility is that such progression in congenital IGHD may occur later in life. However, having worked with this cohort (including providing primary medical care) for more than 20 years, we did not observe any case of clinical liver disease except one portal fibrosis due to *S. mansoni* infection. Furthermore, no liver disease was reported in death certificates of 22 IGHD deceased individuals [@bib22].

The causes of this lack of progression may be multiple. In addition to the high IGF1+IGF2/IGFBP3 ratio, other protective factors may have a role. One of them is the high serum adiponectin level [@bib19], as low adiponectin levels are classically associated with insulin resistance. A second protective factor is the normal leptin [@bib19]. Lack of leptin signaling in leptin-deficient and -resistant mice is associated with NAFLD [@bib31]. The normal leptin serum values of these IGHD individuals suggest normal leptin signaling.

In conclusion, the prevalence of NAFLD and the liver HP score are increased in adults with congenital, lifetime, untreated IGHD, but with only a modest increase in transaminases, suggesting the lack of advanced forms of NAFLD. This finding contrasts with the association of severe forms of NAFLD in acquired hypopituitarism and weakens the hypothesis of a causal relationship of GH/IGF1 deficiency in the pathogenesis of NAFLD.
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###### 

Demographic and anthropometric measurements in isolated GH-deficient IGHD (*n*=22) and control groups, COs (*n*=25). Data are expressed as mean±[s.d.]{.smallcaps}, except for sex.

                    **IGHD**    **CO**      ***P***
  ----------------- ----------- ----------- ----------
  Age (years)       39.3±12.0   37.8±10.9   0.652
  Sex               11 M        10 M        0.595
  Height (m)        1.3±0.1     1.6±0.1     \<0.0001
  SDS height/age    −5.8±1.5    −0.8±0.8    \<0.0001
  Weight (kg)       39.3±7.8    67.4±13.1   \<0.0001
  BMI (kg/m^2^)     24.0±5.0    25.3±4.2    0.329
  Waist (cm)        76.6±10.0   84.8±9.9    0.008
  Hip (cm)          77.6±9.0    93.6±8.9    \<0.0001
  Waist/hip ratio   0.98±0.1    0.90±0.1    \<0.0001

###### 

Laboratorial data in isolated GH-deficient IGHD (*n*=22) and control groups, COs (*n*=25). Data are expressed as mean±[s.d]{.smallcaps}.

                              **IGHD**      **CO**       ***P***
  --------------------------- ------------- ------------ ----------
  IGF1                        33.4±20.7     160.6±51.9   \<0.0001
  Total cholesterol (mg/dl)   200.4±51.2    171.6±28.1   0.027
  LDL-C (mg/dl)               124.9±40.5    102.9±24.2   0.032
  HDL-C (mg/dl)               53.0±12.1     48.7±11.3    0.220
  Triglycerides (mg/dl)       113.2±100.0   98.1±63.6    0.551
  AST (U/l)                   32.6±14.1     24.1±7.1     0.013
  ALT (U/l)                   45.3±28.5     34.4±11.5    0.106
  AST/upper limit             0.8±0.4       0.6±0.2      0.013
  ALT/upper limit             1.0±0.6       0.8±0.3      0.106
  GGT (U/l)                   42.2±37.5     28.9±18.7    0.144
  PT (s)                      10.7±0.7      11.2±0.4     0.017
  PA (%)                      98.1±4.8      97.7±4.3     0.793
  INR (%)                     1.0±0.0       1.0±0.0      0.216
  APTT (s)                    26.8±2.8      26.8±1.4     0.996
  Fibrinogen (mg/dl)          290.7±46.8    272.6±63.3   0.292
  HP                          0.8±0.7       0.4±0.7      0.041

PT, prothrombin time; PA, prothrombin activity; APTT, activated partial thromboplastin time; HP, hyperechogenic pattern: 0, absent; 1, mild, 2, moderate and 3, severe.
